Showing results (41-50 of 55) with videos related to

Sort By:
Pageof 6
Nature Communications|April 25, 2019
Corrupted coordination of epigenetic modifications leads to diverging chromatin states and transcriptional heterogeneity in CLLAlessandro Pastore, Federico Gaiti, Sydney X Lu, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 18, 2021
Venetoclax in Previously Treated Waldenström MacroglobulinemiaJorge J Castillo, John N Allan, Tanya Siddiqi, et al.
British Journal of Haematology|November 5, 2019
The efficacy and safety of venetoclax therapy in elderly patients with relapsed, refractory chronic lymphocytic leukaemiaToby A Eyre, Lindsey E Roeker, Christopher P Fox, et al.
The Journal of Clinical Investigation|September 26, 2023
Hyperphosphorylation of BCL-2 family proteins underlies functional resistance to venetoclax in lymphoid malignanciesStephen Jun Fei Chong, Fen Zhu, Olga Dashevsky, et al.
Nature|May 17, 2019
Epigenetic evolution and lineage histories of chronic lymphocytic leukaemiaFederico Gaiti, Ronan Chaligne, Hongcang Gu, et al.
Blood Advances|February 5, 2024
Hypertension treatment for patients receiving ibrutinib: a multicenter retrospective studyLaura Samples, Jenna Voutsinas, Bita Fakhri, et al.
Clinical Lymphoma, Myeloma & Leukemia|April 19, 2023
Treatment Discontinuation Patterns for Patients With Chronic Lymphocytic Leukemia in Real-World Settings: Results From a Multi-Center International StudyMazyar Shadman, Beenish S Manzoor, Kavita Sail, et al.
American Journal of Hematology|August 23, 2018
Outcomes of front-line ibrutinib treated CLL patients excluded from landmark clinical trialAnthony R Mato, Lindsey E Roeker, John N Allan, et al.
Blood Advances|September 21, 2021
Integrated safety analysis of umbralisib, a dual PI3Kδ/CK1ε inhibitor, in relapsed/refractory lymphoid malignanciesMatthew S Davids, Owen A O'Connor, Wojciech Jurczak, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 21, 2019
Tumor Lysis, Adverse Events, and Dose Adjustments in 297 Venetoclax-Treated CLL Patients in Routine Clinical PracticeLindsey E Roeker, Christopher P Fox, Toby A Eyre, et al.
Pageof 6